Phase I, pilot study in healthy volunteers, to assess the safety and pharmacokinetics of PCO-02, which active ingredient is BPC-157, a pentadecapeptide from gastric source.
Conducted in 2015.
Canceled in 2016 with NO EXPLANATION - either not effective or dangerous.
Conducted in 2015.
Canceled in 2016 with NO EXPLANATION - either not effective or dangerous.
CTG Labs - NCBI
clinicaltrials.gov